Argenica Therapeutics may have cracked the code on treating brain injury, with a ferret study showing its lead drug ARG-007 delivers lasting protection where no approved therapy exists.
With all 92 stroke patients now treated, Argenica’s Phase 2 trial of ARG-007 heads into the critical data lock phase — and the biotech world is watching closely.
Argenica Therapeutics’ ARG-007 has demonstrated compelling neuroprotective effects in preclinical models of traumatic brain injury, reducing brain cell damage and neuroinflammation to levels comparable with non-injured subjects.
Argenica Therapeutics (ASX:AGN) moves closer to a potential breakthrough in stroke treatment as its Phase 2 trial of ARG-007 nears completion with a final safety endorsement from the DSMB.
Argenica Therapeutics (ASX:AGN) has dosed 80% of patients in its Phase 2 trial for ARG-007, a promising stroke therapy, with no adverse safety concerns reported.
With FDA Orphan Drug and Rare Pediatric Disease designations, Argenica Therapeutics (ASX:AGN) strengthens its path forward for ARG-006, a promising treatment for neonatal brain injuries in hypoxic-ischaemic encephalopathy (HIE).